Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

Primary Objective

• The primary efficacy endpoint will be the rate of sCR and/or the rate of negative MRD by
next generation gene sequencing (NGS) by clonoSIGHT (Adaptive Biotechnologies) at the end of
8 cycles among non-transplant candidates and transplant candidates who agreed to defer
transplant

Secondary Objectives

- To evaluate the safety and tolerability of elotuzumab in combination with KRd, when
administered to subjects with newly diagnosed multiple myeloma.

- To determine the rate of MRD by next generation gene sequencing (NGS) by clonoSIGHT
(Adaptive Biotechnologies) and by multi-color flow cytometry (MFC) at the end of Cycle
4, 8,and 12 for all subjects, and end of C18 (for subjects who are MRD+ at the end of C8
but MRD- at the end of C12 only), 24 months after C1D1, and yearly after that.

- To estimate time to event, including duration of response (DOR), progression-free
survival (PFS), time to progression (TTP), and overall survival (OS).

Exploratory Objectives

- GEP, proteomics, and gene sequencing to evaluate the correlation between treatment
outcome and pre-treatment subject profile.

- Immunologic correlative studies including FcγRIIIa V genotype.

Inclusion Criteria:

- Subjects must meet all of the following inclusion criteria to be eligible to enroll in
this study. No enrollment waivers will be granted.

1. Newly diagnosed, previously untreated myeloma requiring systemic chemotherapy

a. Prior treatment of hypercalcemia or spinal cord compression or active and/or
aggressively progressing myeloma with corticosteroids and/or lenalidomide and/or
bortezomib/PI-based regimens does not disqualify the subject (the corticosteroid
treatment dose should not exceed the equivalent of 160 mg of dexamethasone in a 4
week period or not more than 1 cycle of lenalidomide and/or PI-based therapy)

2. Both transplant and non-transplant candidates are eligible.

3. Diagnosis of symptomatic multiple myeloma as per current IMWG uniform criteria
prior to initial treatment

4. Monoclonal plasma cells in the BM 10% or presence of a biopsy-proven plasmacytoma

5. Measurable disease, prior to initial treatment as indicated by one or more of the
following:

1. Serum M-protein ≥ 1 g/dL

2. Urine M-protein ≥ 200 mg/24 hours

3. If serum protein electrophoresis is felt to be unreliable for routine
M-protein measurement, then quantitative immunoglobulin levels are
acceptable (≥ 1 g/dL)

4. Involved serum free light chains ≥ 10 mg/dL provided that free light chain
ratio is abnormal

6. Screening laboratory values must meet the following criteria and should be
obtained within 21 days prior to enrollment WBC ≥ 2000/µL Platelets ≥ 75 x103/µL
ANC >1000/µL Hemoglobin > 8.0 g/dL Serum creatinine ≤ 1.5 x ULN or creatinine
clearance (CrCl) ≥ 50 mL/min

1. Use the Cockcroft-Gault formula below):

o Female CrCl = (140 - age in years) x weight in kg x 0.85

- 72 x serum creatinine in mg/dL

o Male CrCl = (140 - age in years) x weight in kg x 1.00

- 72 x serum creatinine in mg/dL

2. Alternatively to Cockcroft-Gault formula of CrCl, 24hr urine CrCl can be
used AST/ALT ≤ 3 x ULN Total Bilirubin ≤ 1.5 x ULN (except subjects with
Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) or ≤ 2 x ULN if
lenalidomide is being prescribed.

7. Males and females ≥ 18 years of age

8. ECOG performance status of 0-1

9. Females of childbearing potential (FCBP) must have 2 negative pregnancy tests
(sensitivity of at least 50 mIU/mL) prior to initiating lenalidomide. The first
pregnancy test must be performed within 10-14 days before and the second
pregnancy test must be performed within 24 hours before lenalidomide is
prescribed for Cycle 1 (prescriptions must be filled within 7 days).

10. FCBP must agree to use 2 reliable forms of contraception simultaneously or to
practice complete abstinence from heterosexual intercourse during the following
time periods related to this study: 1) for at least 28 days before starting
lenalidomide; 2) while participating in the study; and 3) for at least 28 days
after discontinuation from the study.

11. Male subjects must agree to use a latex condom during sexual contact with females
of childbearing potential while participating in the study and for at least 28
days following discontinuation from the study even if he has undergone a
successful vasectomy.

12. All study participants in the US must be consented to and registered into the
mandatory Revlimid REMS program and be willing and able to comply with the
requirements of Revlimid REMS.

13. Voluntary written informed consent

Exclusion Criteria:

- Subjects meeting any of the following exclusion criteria are not eligible to enroll in
this study. No enrollment waivers will be granted.

1. Non-secretory or hyposecretory multiple myeloma, prior to initial treatment
defined as <1.0 g/dL M-protein in serum, <200 mg/24 hr urine M-protein, and no
measurable disease as per IMWG by Freelite.

2. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein,
and skin changes)

3. Geriatric assessment score of ≥2 as defined by Palumbo et al.

4. Known or suspected Amyloidosis

5. Plasma cell leukemia

6. Within 4 weeks since any plasmapheresis

7. Within 3 weeks of any corticosteroids except per inclusion criteria #2

8. Waldenström's macroglobulinemia or IgM myeloma

9. Participation in an investigational therapeutic study within 3 weeks or within 5
drug half-lives (t1/2) prior to first dose, whichever time is greater

10. Subjects not able to tolerate elotuzumab, lenalidomide, carfilzomib, or
dexamethasone

11. Peripheral neuropathy ≥ Grade 2 at screening

12. Prior CVA with persistent neurological deficit

13. Diarrhea > Grade 1 in the absence of antidiarrheals

14. CNS involvement

15. Corrected calcium ≥ 11.5 mg/dL within 2 weeks of randomization

16. Pregnant or lactating females

17. Radiotherapy within 14 days before randomization. Seven days may be considered if
to single area

18. Major surgery within 3 weeks prior to first dose

19. Subject has clinically significant cardiac disease, including:

- myocardial infarction within 1 year before Cycle 1 Day 1, or an unstable or
uncontrolled disease/condition related to or affecting cardiac function (eg,
unstable angina, congestive heart failure, New York Heart Association Class
III-IV

- uncontrolled cardiac arrhythmia (NCI CTCAE Version 4 Grade 2:2) or
clinically significant ECG abnormalities

- screening 12-lead ECG showing a baseline QT interval as corrected by
Fridericia's formula (QTcF) >470 msec

20. Uncontrolled HTN 14 days prior to enrollment

21. Prior or concurrent deep vein thrombosis or pulmonary embolism

22. Rate-corrected QT interval of electrocardiograph (QTc) > 470 msec on a 12-lead
ECG during screening

23. Uncontrolled hypertension (defined as average systolic blood pressure ≥140 or
average diastolic blood pressure ≥90, with blood pressure measured ≥3 times in
the two weeks prior to enrollment ) or diabetes

24. Acute infection requiring systemic antibiotics, antivirals, or antifungals within
two weeks prior to first dose

25. Active infection

26. Known seropositive for or active viral infection with human immunodeficiency
virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Subjects who are
seropositive because of hepatitis B virus vaccine are eligible.

27. Non-hematologic malignancy or non-myeloma hematologic malignancy within the past
3 years except a) adequately treated basal cell, squamous cell skin cancer,
thyroid cancer, carcinoma in situ of the cervix, or prostate cancer < Gleason
Grade 6 with stable prostate specific antigen levels or cancer considered cured
by surgical resection alone

28. Any clinically significant medical disease or condition that, in the Treating
Investigator's opinion, may interfere with protocol adherence or a subject's
ability to give informed consent